Hostname: page-component-76fb5796d-wq484 Total loading time: 0 Render date: 2024-04-26T15:02:21.862Z Has data issue: false hasContentIssue false
  • English
  • Français

Neuroblastoma and Fetal Exposure to Phenytoin in a Child Without Dysmorphic Features

Published online by Cambridge University Press:  18 September 2015

S. Al-Shammri ,
A. Guberman  and
E. Hsu
S. Al-Shammri
Affiliation:
Division of Neurology, Ottawa General Hospital
A. Guberman*
Affiliation:
Division of Neurology, Ottawa General Hospital
E. Hsu
Affiliation:
Department of Pediatrics, Children’s Hospital of Eastern Ontario
*
Division of Neurology, Ottawa General Hospital, 501 Smyth Road, Ottawa, Ontario, Canada KIH 8L6
Rights & Permissions [Opens in a new window]

Abstract:

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Despite the fact that the teratogenic effects of phenytoin have been suggested in several case reports, the evidence for a possible oncogenic potential of phenytoin has not been widely recognized. Recently, neuroblastoma as well as other neuroectodermal and non-ectodermal tumors has been seen in several children exposed to phenytoin prenatally. Previous cases have been almost uniformly associated with the features of “fetal hydantoin syndrome” and none have been developmentally normal. We report a developmentally-normal boy of 2½ years with an abdominal neuroblastoma whose mother had been on phenytoin (as well as carbamazepine) throughout gestation. We review the various neoplasms which have been reported in the offspring of mothers receiving phenytoin.

Type
Articles
Information
Canadian Journal of Neurological Sciences , Volume 19 , Issue 2 , May 1992 , pp. 243 - 245
Copyright
Copyright © Canadian Neurological Sciences Federation 1992

References

1.Sherman, S, Roizen, N.Fetal hydantoin syndrome and neuroblastoma. Lancet 1976; 2: 517.Google Scholar
2.Pendergrass, TW, Hanson, JW.Fetal hydantoin syndrome and neuroblastoma. Lancet 1976; 2: 150.Google ScholarPubMed
3.Ramilo, J, Harris, VJ.Neuroblastoma in a child with the hydantoin and fetal alcohol syndrome. The radiographic features. Br J Radiol, 1979; 52:993–995.CrossRefGoogle Scholar
4.Allen, RW Jr, Ogden, B, Bentley, FL, Jung, AL.Fetal hydantoin syndrome, neuroblastoma and hemorrhagic disease in a neonate. JAMA 1980; 244: 1464–1465.CrossRefGoogle ScholarPubMed
5.Ehrenbard, LT, Chagantirs, K.Cancer in the fetal hydantoin syndrome. Lancet 1981; 2: 97.Google ScholarPubMed
6.Koren, G, Demitrakoudis, D, Weksberg, R, et al. Neuroblastoma after prenatal exposure to phenytoin: cause and effect? Teratology 1989; 40: 157–162.Google ScholarPubMed
7.Leppik, IE.Management of seizures during pregnancy. In: Pedley, TA, Meldrum, BS, eds. Recent Advances in Epilepsy-4. Edinburgh: Churchill Livingstone 1988; 109–121.Google Scholar
8.Hanson, JW, Smith, DW.The fetal hydantoin syndrome. J Pediatr 1975; 87: 285–290.CrossRefGoogle ScholarPubMed
9.Yerby, MS.Teratogenicity of antiepileptic drugs. In: Pedley, TA, Meldrum, BS, eds. Recent Advances in Epilepsy-4. Edinburgh; Churchill Livingstone 1988; 93–107.Google Scholar
10.Seeler, RA, Israel, JN, Royal, JE, et al. Ganglioneuroblastoma and fetal hydantoin syndrome. Pediatrics 1979; 63: 524–527.CrossRefGoogle Scholar
11.Jimenez, JF, Seibert, RW, Char, F, Brown, RE, Seibert, JJ.Melanotic neuroectodermal tumor of infancy and fetal hydantoin syndrome. Am J Pediatr Hematol/Oncol 1981; 3: 9–15.Google ScholarPubMed
12.Lipson, A, Bale, P.Ependymoblastoma associated with prenatal exposure to diphenylhydantoin and methylphenobarbitone. Cancer 1985; 55: 1859–1862.3.0.CO;2-F>CrossRefGoogle ScholarPubMed
13.Blattner, WA, Hensen, DE, Young, RC, Fraumeni, JF Jr. Malignant mesenchymoma and birth defects. JAMA 1977; 238: 334–335.CrossRefGoogle ScholarPubMed
14.Taylor, WF, Myers, M, Taylor, WR.Extrarenal Wilms’ tumor in an infant exposed to intrauterine phenytoin. Lancet 1980; 2: 481–482.CrossRefGoogle Scholar
15.Bostrom, B, Nesbit, ME Jr. Hodgkin disease in a child with fetal alcohol-hydantoin syndrome. J Pediatr 1983; 103: 760–762.CrossRefGoogle Scholar
16.Sholler, GF, Hawker, RE, Nunn, GR, Bale, P, Bergin, M.Primary left ventricular rhabdomyosarcoma in a child: noninvasive assessment and successful resection of a rare tumor. J Thorac Cardiovasc Surg 1987; 93: 465–472.CrossRefGoogle Scholar
17.Krueger, GR, Bedoya, VA.Hydantoin-induced lymphadenopathies and lymphomas: experimental studies in mice. Recent Res Cancer Res 1978; 64: 265.CrossRefGoogle ScholarPubMed
18.Jang, JJ, Takahashi, M, Furukawa, F, et al. Long-term in vivo carcinogenicity study of phenytoin (5–5-Diphenylhydantoin) in F344 rats. Fd Chem Tox 1987; 25: 697–702.CrossRefGoogle ScholarPubMed
19.Blake, DA, Fallinger, C.Embryopathic interaction of phenytoin and trichloropropene oxide in mice. Teratology 1976; 13: 17A.Google Scholar
20.Nebert, DW, Jensen, NM.The Ah locus: genetic regulation of the metabolism of carcinogens, drugs and other environmental chemicals by cytochrome P-450 mediated mono-oxygenases. CRC Crit Rev Biochem 1979; 6: 402–437.CrossRefGoogle Scholar
21.Jerina, DM, Daly, JW.Arene oxides: a new aspect of drug metabolism. Science 1974; 185: 573–581.CrossRefGoogle ScholarPubMed